Physician profile
Duane Whitlock
NPI 1821098229
$4,811.03
in general payments reported to CMS, 2019-2025
26 companies · $661 in 2025
The $661 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $318 · 2021: $832 · 2022: $822 · 2023: $685 · 2024: $1,083 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Education: $118 · Honoraria: $25.59 · Gift: $21.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.70 |
| Education | $117.83 |
| Honoraria | $25.59 |
| Gift | $21.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $825.09 | 2019-2025 | Cequa, Xelpros |
| Mallinckrodt Hospital Products INC. | $651.86 | 2020-2024 | Acthar |
| Alcon Vision LLC | $622.75 | 2019-2025 | Rocklatan, Argos, Clareon |
| Abbvie INC. | $437.18 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb Americas INC. | $352.77 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $307.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $260.17 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $221.35 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $216.19 | 2019-2021 | |
| Oyster Point Pharma, INC. | $153.56 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $146.89 | 2019-2021 | |
| Biotissue Holdings INC. | $102.85 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $85.66 | 2024-2025 | Xdemvy |
| Rxsight INC | $69.30 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $57.30 | 2024 | Radius, Istent Trabecular Micro-Bypass System Model Is3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $56.87 | 2023-2024 | Iyuzeh |
| Horizon Therapeutics Plc | $53.25 | 2021-2023 | Tepezza |
| Dompe US, INC. | $50.36 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $25.71 | 2022 | |
| Mallinckrodt Enterprises LLC | $19.94 | 2019 | |
| Amgen INC. | $19.03 | 2024 | Tepezza |
| Akorn Operating Company LLC | $16.72 | 2021 | |
| Ocular Therapeutix, INC. | $16.22 | 2021 | |
| Shire North American Group INC | $15.50 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.99 | 2025 | Exparel |
| Celularity INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Whitlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.